Analysis of Sleep Apnea Clinical Trials Reveals Promising Pipeline from 22 Companies

A recent report by DelveInsight outlines significant developments in the sleep apnea clinical trial landscape, detailing active contributions from over 22 pharmaceutical companies focused on more than 24 pipeline drugs targeting the disorder.

The 'Sleep Apnea Pipeline Insight 2026' report provides a comprehensive overview of global therapies for sleep apnea at various clinical stages. It highlights key trends, emerging therapies, and the competitive landscape as major companies seek to enhance treatment options and capture growth opportunities. The report emphasizes critical data on clinical trial benchmarks, as well as partnering and licensing trends involving the FDA and EMA, guiding stakeholders in their development strategies.

Companies such as Novo Nordisk A/S, Eli Lilly and Company, Mosanna Therapeutics, and Apnimed are among the leading contributors to the pipeline aimed at improving the treatment of sleep apnea. Prominent therapies in development include Zenagamtide, IBI362, AD109, and others, which are at different phases of clinical trials. Currently, over 8 drugs are in the final stages of development, with various mechanisms of action, such as GLP-1 receptor agonists and cannabinoid receptor agonists, being explored.

Sleep apnea is a prevalent sleep disorder characterized by repeated breathing interruptions during sleep, leading to various health risks if untreated, including cardiovascular issues and metabolic disorders.

In July 2026, Apnimed, Inc. successfully submitted a New Drug Application for AD109 to the FDA, with a target action date set for February 28, 2027. Additionally, Mosanna Therapeutics recently secured $80 million in funding to develop a novel nasal spray treatment for obstructive sleep apnea. In April 2025, Apnimed initiated a clinical trial for SASS-001, aiming to treat patients with a central component of sleep apnea. Shionogi & Co., Ltd. also announced a collaboration with Apnimed regarding the development of sulthiame for obstructive sleep apnea.

Overall, the landscape for sleep apnea treatment is anticipated to evolve, focusing on personalized approaches influenced by various patient-specific factors. The ongoing clinical developments signal a favorable outlook for innovative pharmacological therapies aimed at enhancing treatment adherence and patient outcomes.